Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Data from S.P. Buchbinder and colleagues advance knowledge in HIV/AIDS
January 7th, 2009
According to recent research from the United States, " Observational data and non-human primate challenge studies suggest that cell-mediated immune responses might provide control of HIV replication. The Step Study directly assessed the efficacy of a cell-mediated immunity, vaccine to protect against HIV-1 infection or change in early plasma HIV-1 levels." " We undertook a double-blind, phase 11, test-of-concept study at 34 sites in North America, the Caribbean, South America, and Australia. We randomly assigned 3000 HIV-1-seronegative participants by computer-generated assignments to receive three injections of MRKAd5 HIV-1 gag/pol/nef vaccine (n=1494) or placebo...
Source: Vaccine Weekly (2009-01-07)
|
